Rapid ID+AST pilot study highlighted at ECCMID 2020
The pilot study, led by Gradientech, combined rapid ID+AST technologies – T2Bacteria (ID) and QuickMIC (AST) and compared the time-to-result to a workflow using standard laboratory methods.
The rapid diagnostic workflow provided same-shift results (9.5h) that were significantly faster than the standard workflow (53h). Interestingly, in 68% of the cases, rapid ID+AST results were available before blood cultures had turned positive.
This study highlights the potential of combining rapid ID+AST diagnostic technologies for reducing the time to targeted treatment initiation for sepsis patients.
For further information, please contact:
Sara Thorslund, PhD, CEO Gradientech
Tel: +46 736 29 35 80
Next-generation antimicrobial susceptibility testingTake a look at our E-book